BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35866817)

  • 21. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH.
    de Biase D; Acquaviva G; Visani M; Marucci G; De Leo A; Maloberti T; Sanza V; Di Oto E; Franceschi E; Mura A; Ragazzi M; Serra S; Froio E; Bisagni A; Brandes AA; Pession A; Tallini G
    J Mol Diagn; 2021 Sep; 23(9):1185-1194. PubMed ID: 34186176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.
    Ren X; Cui X; Lin S; Wang J; Jiang Z; Sui D; Li J; Wang Z
    PLoS One; 2012; 7(3):e32764. PubMed ID: 22427879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
    Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P
    Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
    Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
    J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
    Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.
    Balakumar S; Pai R; Chacko AG; Patel B; Nancy R; Balakrishnan R; Sarkar S; Sampath G; Chacko G
    Neurol India; 2022; 70(3):953-959. PubMed ID: 35864624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Static and dynamic
    Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent oligodendroglioma with changed 1p/19q status.
    Barresi V; Mafficini A; Calicchia M; Piredda ML; Musumeci A; Ghimenton C; Scarpa A
    Neuropathology; 2022 Apr; 42(2):160-166. PubMed ID: 35144313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 37. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
    ; Brat DJ; Verhaak RG; Aldape KD; Yung WK; Salama SR; Cooper LA; Rheinbay E; Miller CR; Vitucci M; Morozova O; Robertson AG; Noushmehr H; Laird PW; Cherniack AD; Akbani R; Huse JT; Ciriello G; Poisson LM; Barnholtz-Sloan JS; Berger MS; Brennan C; Colen RR; Colman H; Flanders AE; Giannini C; Grifford M; Iavarone A; Jain R; Joseph I; Kim J; Kasaian K; Mikkelsen T; Murray BA; O'Neill BP; Pachter L; Parsons DW; Sougnez C; Sulman EP; Vandenberg SR; Van Meir EG; von Deimling A; Zhang H; Crain D; Lau K; Mallery D; Morris S; Paulauskis J; Penny R; Shelton T; Sherman M; Yena P; Black A; Bowen J; Dicostanzo K; Gastier-Foster J; Leraas KM; Lichtenberg TM; Pierson CR; Ramirez NC; Taylor C; Weaver S; Wise L; Zmuda E; Davidsen T; Demchok JA; Eley G; Ferguson ML; Hutter CM; Mills Shaw KR; Ozenberger BA; Sheth M; Sofia HJ; Tarnuzzer R; Wang Z; Yang L; Zenklusen JC; Ayala B; Baboud J; Chudamani S; Jensen MA; Liu J; Pihl T; Raman R; Wan Y; Wu Y; Ally A; Auman JT; Balasundaram M; Balu S; Baylin SB; Beroukhim R; Bootwalla MS; Bowlby R; Bristow CA; Brooks D; Butterfield Y; Carlsen R; Carter S; Chin L; Chu A; Chuah E; Cibulskis K; Clarke A; Coetzee SG; Dhalla N; Fennell T; Fisher S; Gabriel S; Getz G; Gibbs R; Guin R; Hadjipanayis A; Hayes DN; Hinoue T; Hoadley K; Holt RA; Hoyle AP; Jefferys SR; Jones S; Jones CD; Kucherlapati R; Lai PH; Lander E; Lee S; Lichtenstein L; Ma Y; Maglinte DT; Mahadeshwar HS; Marra MA; Mayo M; Meng S; Meyerson ML; Mieczkowski PA; Moore RA; Mose LE; Mungall AJ; Pantazi A; Parfenov M; Park PJ; Parker JS; Perou CM; Protopopov A; Ren X; Roach J; Sabedot TS; Schein J; Schumacher SE; Seidman JG; Seth S; Shen H; Simons JV; Sipahimalani P; Soloway MG; Song X; Sun H; Tabak B; Tam A; Tan D; Tang J; Thiessen N; Triche T; Van Den Berg DJ; Veluvolu U; Waring S; Weisenberger DJ; Wilkerson MD; Wong T; Wu J; Xi L; Xu AW; Yang L; Zack TI; Zhang J; Aksoy BA; Arachchi H; Benz C; Bernard B; Carlin D; Cho J; DiCara D; Frazer S; Fuller GN; Gao J; Gehlenborg N; Haussler D; Heiman DI; Iype L; Jacobsen A; Ju Z; Katzman S; Kim H; Knijnenburg T; Kreisberg RB; Lawrence MS; Lee W; Leinonen K; Lin P; Ling S; Liu W; Liu Y; Liu Y; Lu Y; Mills G; Ng S; Noble MS; Paull E; Rao A; Reynolds S; Saksena G; Sanborn Z; Sander C; Schultz N; Senbabaoglu Y; Shen R; Shmulevich I; Sinha R; Stuart J; Sumer SO; Sun Y; Tasman N; Taylor BS; Voet D; Weinhold N; Weinstein JN; Yang D; Yoshihara K; Zheng S; Zhang W; Zou L; Abel T; Sadeghi S; Cohen ML; Eschbacher J; Hattab EM; Raghunathan A; Schniederjan MJ; Aziz D; Barnett G; Barrett W; Bigner DD; Boice L; Brewer C; Calatozzolo C; Campos B; Carlotti CG; Chan TA; Cuppini L; Curley E; Cuzzubbo S; Devine K; DiMeco F; Duell R; Elder JB; Fehrenbach A; Finocchiaro G; Friedman W; Fulop J; Gardner J; Hermes B; Herold-Mende C; Jungk C; Kendler A; Lehman NL; Lipp E; Liu O; Mandt R; McGraw M; Mclendon R; McPherson C; Neder L; Nguyen P; Noss A; Nunziata R; Ostrom QT; Palmer C; Perin A; Pollo B; Potapov A; Potapova O; Rathmell WK; Rotin D; Scarpace L; Schilero C; Senecal K; Shimmel K; Shurkhay V; Sifri S; Singh R; Sloan AE; Smolenski K; Staugaitis SM; Steele R; Thorne L; Tirapelli DP; Unterberg A; Vallurupalli M; Wang Y; Warnick R; Williams F; Wolinsky Y; Bell S; Rosenberg M; Stewart C; Huang F; Grimsby JL; Radenbaugh AJ; Zhang J
    N Engl J Med; 2015 Jun; 372(26):2481-98. PubMed ID: 26061751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
    Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
    Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.